Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: Results of prospective trials

I. Choi, R. Tanosaki, N. Uike, A. Utsunomiya, M. Tomonaga, M. Harada, T. Yamanaka, M. Kannagi, J. Okamura

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL) - a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients.

Original languageEnglish
Pages (from-to)116-118
Number of pages3
JournalBone Marrow Transplantation
Volume46
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

    Fingerprint

Keywords

  • HTLV-1 proviral load
  • adult T-cell leukemia/lymphoma
  • allogeneic hematopoietic SCT
  • reduced-intensity conditioning regimen

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Choi, I., Tanosaki, R., Uike, N., Utsunomiya, A., Tomonaga, M., Harada, M., Yamanaka, T., Kannagi, M., & Okamura, J. (2011). Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: Results of prospective trials. Bone Marrow Transplantation, 46(1), 116-118. https://doi.org/10.1038/bmt.2010.92